NCT07179055 An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
| NCT ID | NCT07179055 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Vanda Pharmaceuticals |
| Condition | Dry Eye |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2025-10 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 160 participants in total. It began in 2025-10 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
Eligibility Criteria
Inclusion Criteria: * Be at least 18 years of age of either gender and any race. * Provide written informed consent and sign the HIPAA form. * Be willing and able to follow all instructions and attend all study visits. Exclusion Criteria: * Use of any of the disallowed medications during the washout and study period.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07179055 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dry Eye. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07179055 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07179055 currently recruiting?
Yes, NCT07179055 is actively recruiting participants. Contact the research team at clinicaltrials@vandapharma.com for enrollment information.
Where is the NCT07179055 trial being conducted?
This trial is being conducted at Newport Beach, United States, Andover, United States, Shelby, United States, Memphis, United States and 1 additional location.
Who is sponsoring the NCT07179055 clinical trial?
NCT07179055 is sponsored by Vanda Pharmaceuticals. The trial plans to enroll 160 participants.